Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases.
BACKGROUND
Both hepatic arterial infusion (HAI) of chemotherapy and cetuximab (CET) have interesting activity for the treatment of colorectal cancer liver metastases (CRC-LM).


METHODS
Intravenous CET with HAI oxaliplatin (OXA) or i.v. Irinotecan (IRI) followed by HAI of infusion of folic acid modulated 5-fluorouracil 5-FU/l-FA was administered to patients (pts) with CRC-LM who had failed at least one line of prior chemotherapy.


RESULTS
Eight pts received i.v. CET with HAI-OXA (5 pts) and i.v.-IRI (3 pts) and HAI-5-FU/l-FA. Adverse events: repeated grade 3 skin toxicity (1 pt), abdominal pain with elevated liver enzymes and asthenia (2 pts), duodenal ulcer (2 pts) with catheter migration and intestinal bleeding (1 pt), reversible interstitial pneumonitis (1 pt), and cystic bile duct dilatation (2 pts) with arteriobiliary fistulisation (1 pt). A partial response was documented in 5 pts (62%). The median time to progression was 8.7 months (95% confidence interval 8-14 months).


CONCLUSIONS
Intravenous administration of CET with HAI of chemotherapy is feasible and has promising activity but is associated with specific toxicity.
Neyns
Bart
B
Medical Oncology, UZ Brussel, Brussels, Belgium. Bart.Neyns@uzbrussel.be
Aerts
Maridi
M
Van Nieuwenhove
Yves
Y
Fontaine
Christel
C
De Coster
Lore
L
Schallier
Dennis
D
Vanderauwera
Jacques
J
De Munck
Floris
F
Vandenbroucke
Frederik
F
Everaert
Hendrik
H
Meert
Vanessa
V
De Mey
Johan
J
De Ridder
Mark
M
Delvaux
Georges
G
De Grève
Jacques
J